Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PLAQUENIL vs ARALEN HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Antimalarial and immunosuppressant; inhibits heme polymerase in Plasmodium, preventing conversion of toxic heme to hemozoin; also inhibits lysosomal function, antigen presentation, and cytokine production (e.g., IL-1, TNF-alpha) in autoimmune diseases.
Chloroquine, a 4-aminoquinoline, accumulates in acidic organelles such as lysosomes and food vacuoles of malaria parasites, raising p H and inhibiting hemozoin polymerization, which leads to toxic heme accumulation and parasite death. It also has anti-inflammatory and immunomodulatory effects by inhibiting TLR signaling and cytokine production.
Treatment of uncomplicated malaria due to P. falciparum, P. vivax, P. ovale, and P. malariae,Prophylaxis of malaria,Treatment of systemic lupus erythematosus,Treatment of rheumatoid arthritis,Off-label: Treatment of discoid lupus erythematosus, sarcoidosis, porphyria cutanea tarda, and Q fever
Treatment of uncomplicated malaria due to chloroquine-sensitive Plasmodium species,Prophylaxis of malaria in areas with chloroquine-sensitive parasites,Extraintestinal amebiasis,Treatment of discoid lupus erythematosus (off-label),Treatment of rheumatoid arthritis (off-label)
400 mg (310 mg base) orally daily, or 400 mg/day in divided doses; maintenance: 200-400 mg/day
Chloroquine phosphate 500 mg (300 mg base) orally once weekly for prophylaxis; 600 mg base (1 g phosphate) orally initially, followed by 300 mg base (500 mg phosphate) at 6, 24, and 48 hours for treatment of malaria.
Terminal elimination half-life: 32-50 days (range 22-124 days) due to extensive tissue distribution and slow release from melanin-rich tissues; requires long-term dosing to achieve steady state (3-6 months).
48-72 hours (terminal elimination half-life); prolonged to weeks with chronic dosing due to extensive tissue accumulation, especially in the liver, spleen, and melanin-containing tissues.
Hepatic metabolism primarily via CYP2D6, CYP3A4, and CYP2C8; partially excreted unchanged in urine.
Hepatic metabolism via CYP2C8, CYP3A4, and CYP2D6 to desethylchloroquine and other metabolites.
Renal (50-70% unchanged), fecal (20-30% as metabolites), minor biliary.
Renal (~70% unchanged), with 10-20% in feces; biliary elimination is minor.
~50% bound to plasma proteins (primarily albumin).
50-60%, primarily to albumin and α1-acid glycoprotein.
Extensive: 500-800 L/kg (total Vd), indicating deep tissue sequestration (e.g., eyes, skin, liver, kidneys).
50-100 L/kg; extensive tissue sequestration including erythrocytes, liver, spleen, and melanin-containing tissues like skin and retina.
Oral: ~75% (range 67-90%) with interindividual variability; food may increase absorption.
Oral: ~70-80% (variable due to first-pass metabolism); intravenous: 100%.
No specific guidelines; caution with severe impairment (Cr Cl <30 m L/min) – reduce dose by 50% or extend interval
Severe renal impairment (GFR <10 m L/min): reduce dose by 50% or increase dosing interval.
No specific guidelines; caution with severe hepatic impairment (Child-Pugh C) – consider dose reduction by 50%
Use with caution in patients with hepatic impairment; no specific dose adjustment guidelines available; contraindicated in severe hepatic disease or porphyria.
6.5 mg/kg (base) orally daily, maximum 400 mg/day; malaria: 13 mg/kg base initially, then 6.5 mg/kg at 6, 24, and 48 hours
Prophylaxis: 5 mg base/kg orally once weekly (max 300 mg base). Treatment: 10 mg base/kg orally initially, then 5 mg base/kg at 6, 24, and 48 hours (max 600 mg base total).
Start at lower end of dosing range; monitor for retinal toxicity (cumulative dose >1000 g or >5 years use)
Start at lower end of dosing range due to increased risk of adverse effects (e.g., QT prolongation, retinal toxicity); monitor renal function.
No FDA boxed warning.
No FDA black box warning.
Retinal toxicity: Dose-related, cumulative risk; baseline and annual ophthalmologic exams recommended,Cardiomyopathy: Rare but potentially fatal; discontinue if signs of conduction abnormalities or heart failure develop,Hypoglycemia: Can occur, particularly in patients with diabetes or on antidiabetic agents,QT prolongation: Risk increased with concurrent use of other QT-prolonging drugs or electrolyte disturbances,Myopathy/neuropathy: Reversible upon discontinuation,Blood dyscrasias: Monitor for unexplained infection, bruising, or bleeding
Retinopathy and irreversible retinal damage with prolonged use or high doses; requires baseline and periodic ophthalmologic exams,QT prolongation and ventricular arrhythmias, especially with concomitant QT-prolonging drugs or electrolyte abnormalities,Severe hypoglycemia including loss of consciousness,Neuropsychiatric effects including psychosis and suicidal ideation,Hemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficiency
Hypersensitivity to hydroxychloroquine or 4-aminoquinoline derivatives,Pre-existing retinopathy of any etiology,Long-term therapy in children (not a contraindication for short-term malaria treatment)
Hypersensitivity to chloroquine or any 4-aminoquinoline,Pre-existing retinopathy or known maculopathy,Known G6PD deficiency (relative, use with caution),Concomitant use with strong QT-prolonging drugs (e.g., quinidine, procainamide)
No significant food interactions. Taking with food or milk may reduce gastrointestinal upset.
Avoid grapefruit and grapefruit juice as they may increase drug levels and toxicity. Limit alcohol intake to reduce risk of liver toxicity. Administer with food to decrease gastrointestinal irritation. Avoid antacids containing aluminum or magnesium; separate by at least 4 hours.
Plaquenil (hydroxychloroquine) is not associated with major teratogenic effects. First trimester exposure: no increased risk of major malformations above baseline. Second and third trimesters: possible low risk of fetal hearing loss and retinal toxicity with maternal long-term use. No documented fetal cardiotoxicity.
Chloroquine hydrochloride crosses the placenta. First trimester: associated with increased risk of spontaneous abortion and congenital abnormalities (cochleovestibular and ocular) at high doses. Second and third trimesters: possible ototoxicity and retinal toxicity; use only for malaria prophylaxis or treatment when benefit outweighs risk.
Hydroxychloroquine is excreted into breast milk in small amounts. Milk-to-plasma ratio approximately 0.45. Amount ingested by infant relative to maternal dose is less than 2%. No adverse effects in nursing infants reported. Considered compatible with breastfeeding.
Chloroquine is excreted into breast milk in low concentrations (M/P ratio approximately 0.1-0.3). Amounts are unlikely to cause adverse effects in nursing infants. The American Academy of Pediatrics considers chloroquine compatible with breastfeeding. Monitor infant for potential ocular effects.
No dose adjustment required based on pregnancy pharmacodynamics. Hydroxychloroquine clearance does not change significantly in pregnancy. Continue same dose as preconception.
Increased volume of distribution and clearance during pregnancy may require higher doses for malaria prophylaxis (e.g., 400 mg base weekly) and treatment; therapeutic drug monitoring recommended for optimal dosing. No standard dose adjustment established; base dose on indication and clinical response.
Plaquenil (hydroxychloroquine) can cause irreversible retinopathy; cumulative dose > 5 g/kg increases risk. Obtain baseline and annual eye exams. Do not co-administer with QT-prolonging drugs. Check G6PD level before starting (can cause hemolysis in deficiency). Use with caution in renal or hepatic impairment, myasthenia gravis, and psoriasis.
ARALEN HYDROCHLORIDE (chloroquine hydrochloride) is used for malaria prophylaxis and treatment, and for amebiasis. Monitor for retinal toxicity with long-term use; baseline and periodic ophthalmologic exams recommended. Caution in patients with hepatic disease, G6PD deficiency, or porphyria. May exacerbate psoriasis and myasthenia gravis. QT prolongation possible; avoid with other QT-prolonging drugs. Administer with food to reduce GI upset. For acute malaria, dose may be divided to improve tolerance. In severe malaria, use parenteral form with cardiac monitoring.
Take exactly as prescribed; do not increase dose or stop without consulting doctor.,Report vision changes, such as blurred vision or difficulty reading, immediately.,May take with food or milk to reduce upset stomach.,Avoid alcohol while taking this medication.,Tell all healthcare providers you are taking hydroxychloroquine.,Do not take with antacids or kaolin; separate by at least 4 hours.
Take this medication exactly as prescribed; do not skip doses for malaria prophylaxis.,If vomiting occurs within 1 hour of a dose, contact your healthcare provider for instructions.,Report any vision changes, such as blurred vision or difficulty focusing, immediately.,Avoid alcohol and limit caffeine intake as they may increase gastrointestinal side effects.,Use effective contraception during treatment if you are of childbearing potential.,Do not take antacids or kaolin within 4 hours of this medication.,Seek medical attention if you experience signs of allergic reaction: rash, hives, swelling, or difficulty breathing.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PLAQUENIL vs ARALEN HYDROCHLORIDE, answered by our medical review team.
PLAQUENIL is a Antimalarial that works by Antimalarial and immunosuppressant; inhibits heme polymerase in Plasmodium, preventing conversion of toxic heme to hemozoin; also inhibits lysosomal function, antigen presentation, and cytokine production (e.g., IL-1, TNF-alpha) in autoimmune diseases.. ARALEN HYDROCHLORIDE is a Antimalarial that works by Chloroquine, a 4-aminoquinoline, accumulates in acidic organelles such as lysosomes and food vacuoles of malaria parasites, raising p H and inhibiting hemozoin polymerization, which leads to toxic heme accumulation and parasite death. It also has anti-inflammatory and immunomodulatory effects by inhibiting TLR signaling and cytokine production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PLAQUENIL and ARALEN HYDROCHLORIDE depend on the specific clinical indication. These are both Antimalarial agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PLAQUENIL is: 400 mg (310 mg base) orally daily, or 400 mg/day in divided doses; maintenance: 200-400 mg/day. The standard adult dose of ARALEN HYDROCHLORIDE is: Chloroquine phosphate 500 mg (300 mg base) orally once weekly for prophylaxis; 600 mg base (1 g phosphate) orally initially, followed by 300 mg base (500 mg phosphate) at 6, 24, and 48 hours for treatment of malaria.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PLAQUENIL and ARALEN HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PLAQUENIL is classified as Category C. Plaquenil (hydroxychloroquine) is not associated with major teratogenic effects. First trimester exposure: no increased risk of major malformations above baseline. Second and third. ARALEN HYDROCHLORIDE is classified as Category C. Chloroquine hydrochloride crosses the placenta. First trimester: associated with increased risk of spontaneous abortion and congenital abnormalities (cochleovestibular and ocular) . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.